[ad_1]
The authorization of anti-Covid vaccines represents an important opportunity for science, the economy and humanity. But, as many recalled in the last hours Wall Street Analysts, I’m certainly also a major gain for the companies that develop them.
Earnings that from Wall Street find a precise quantification: Pfizer and modern They will $ 32 billion in revenue in 2021 thanks to the Covid vaccine.
An advance in terms of profits that could be incredible for Moderna, a young biotech company that is now on the verge of obtaining own FDA clearance, could soon jump to the top of the ranking of the world’s leading pharmaceutical giants.
Pfizer and Moderna: $ 32 billion worth of vaccines in 2021 alone
According to Morgan Stanley, Pfizer should only generate $ 19 billion in revenue of the Covid vaccine in 2021.
While for 2020, revenue from the vaccine alone could mark $ 975 million. It should be remembered that Pfizer share your income with BioNTech, the German company with which it collaborated in the development of the drug.
However, the advance of the vaccine did not cause a boom in Pfizer’s stock price; This is because it is already a large and established company, and the rapid move towards anti-covid preparedness was more than predictable.
A completely different speech for Moderna, a reality in the start-up phase that could become a giant valued at 62,000 million dollars in a few months. In fact, their stocks have skyrocketed, as + 700% this year, and Morgan Stanley estimates that about half of the company’s market value is currently attributable to the vaccine.
According to Goldman Sachs, Moderna will raise $ 13.2 billion in Covid vaccine revenue next year, while Morgan Stanley expects earnings of up to $ 15 billion.
